Good point regarding the options OGF. By my estimate and your own, we should have $2 million going into April (plus the option excise in June) so no need for CR just now and better to wait until after DD results IMO. We both agree but sometimes management like to raise before they have to.
Everything is going well on the exploration front, DD in progress, assay delays have been resolved and CR or no CR, the share price will quickly right itself.
From what I can see 6 million due for exercise on 30 June 2022.
2 million @ $0.04 = $80,000 4 million @ $0.10 = $400,000
GBR Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
